News | January 29, 2026
CitiusTech & Ventra Health unveil AI-powered revenue game-changer
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The new functionality complements Parse’s existing Evercode immune products
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
The partnership initially will focus on cardiovascular and kidney diseases
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Subscribe To Our Newsletter & Stay Updated
